A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2018
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DAYBREAK; Daybreak Study; DAYBREAK-ALZ
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Apr 2021 to 1 Mar 2021.
- 25 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
- 10 Jun 2017 Biomarkers information updated